about
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsRational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models.Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureTranslating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsImmunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsPotent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infectionProtective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens.A randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium falciparum gametocytemia in the controlled human malaria infection model.Assessing Plasmodium falciparum transmission in mosquito-feeding assays using quantitative PCR.DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected withModeling the dynamics of gametocytes in humans during malaria infectionA Plasmodium vivax experimental human infection model for evaluating the efficacy of interventionsInvestigating the impact of enhanced community case management and monthly screening and treatment on the transmissibility of malaria infections in Burkina Faso: study protocol for a cluster-randomised trialA phase 1, placebo controlled, randomised, single ascending dose study and a volunteer infection study to characterize the safety, pharmacokinetics and antimalarial activity of the Plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048A randomized clinical trial to compare P. falciparum gametocytaemia and infectivity following blood-stage or mosquito bite induced controlled malaria infectionA Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy VolunteersAn Experimental Human Blood-Stage Model for Studying Plasmodium malariae Infection
P50
Q28731894-3E9728EC-8581-463E-9A67-F6ABDAEAC815Q33572458-33FB2FEB-7B25-4B23-A0E6-987DF0239560Q33577093-71786B52-A515-4D21-A9ED-50B47999F11CQ33974904-502AE196-7456-404E-86C6-49F141874DD3Q34257253-154832F6-CA17-482B-92CA-2741810B70FFQ34301461-619AA676-FBB6-4BFC-B6C6-9ACFB72AB4BCQ34529382-B54EB6C7-5724-4E11-AC26-83427BEDFE6DQ34634002-4008B992-EAEF-456A-9061-7A65C68FCC72Q34699088-782755FA-F249-4A7A-8B14-1A18E4765C70Q35163318-F2989671-D9A4-48E1-B573-F2DCBC9AFDD6Q35623459-48F93DB6-2E9A-4A6E-BF87-B51551B314EEQ35741984-DFD4F5A4-5231-4823-9A7C-D21BFDA7AEB3Q35771456-C5EB722A-5AAC-4206-B648-53D1F07A2BF0Q36460499-693DA383-C547-4CE6-8C6A-18A30C9A12F4Q36903515-1717EC63-5ED2-4695-8A2D-001A34D93F82Q37403767-97264260-7155-40B3-87C4-0A204ADB75A5Q37641378-27638BC6-BB28-4FE1-BA47-6270057303C2Q47547431-C90A795F-96C3-476A-8C9D-6640F9704AEBQ48018507-35B700D5-5043-40CD-83FA-29C2F74445E9Q50318730-547B709C-4AC1-42EA-941A-A1B17DA74F75Q55662003-AF7B01B2-2D24-4C3B-BA7E-AD1CC8903039Q64110172-979EE823-C254-40AB-AB05-5BD9D1355677Q83227531-B1564CE5-2B8E-446E-95EB-7D3CED28449FQ89655220-D43E7D04-9582-42DA-973D-E968A396186BQ90099840-C76A3C34-98BF-487D-AB9A-D3006AB07790Q90837866-AC756A81-ED4F-4F60-9AD9-49A4B5AAABFAQ90837907-E9D01691-17F2-46D9-94B9-8C9CFFE16A52Q91104014-E5223218-E806-4134-ABBE-BE9EBBB769D4Q92247710-06AAC3E4-20B0-4E7C-B059-7EB8C4B6C330
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Katharine A Collins
@ast
Katharine A Collins
@en
Katharine A Collins
@es
Katharine A Collins
@nl
Katharine A Collins
@sl
type
label
Katharine A Collins
@ast
Katharine A Collins
@en
Katharine A Collins
@es
Katharine A Collins
@nl
Katharine A Collins
@sl
prefLabel
Katharine A Collins
@ast
Katharine A Collins
@en
Katharine A Collins
@es
Katharine A Collins
@nl
Katharine A Collins
@sl
P1053
N-4369-2015
P106
P21
P31
P3829
P496
0000-0002-7080-2215